An epidemiological study to evaluate the use of vitamin K antagonists and new oral anticoagulants among non-valvular atrial fibrillation patients in Turkey- AFTER-2 study design

Basit Öğe Kaydı
dc.contributor.authorErtas, Faruk
dc.contributor.authorKaya, Hasan
dc.contributor.authorYildiz, Abdulkadir
dc.contributor.authorDavutoglu, Vedat
dc.contributor.authorKiris, Abdulkadir
dc.contributor.authorDinc, Lale
dc.contributor.authorKafes, Habibe
dc.date.accessioned2020-03-26T19:00:45Z
dc.date.available2020-03-26T19:00:45Z
dc.date.issued2015
dc.departmentSelçuk Üniversitesien_US
dc.description.abstractObjectives: Atrial fibrillation (AF) is one of the most common causes of preventable ischemic stroke and is related to increased cardiovascular morbidity and mortality. There is a lack of data in Turkey on the use of new oral anticoagulants (NOACs), and time in therapeutic INR range (TTR) in vitamin K antagonist users and AF management modality. In this multi-center trial, we aimed to analyze, follow and evaluate the epidemiological data in non-valvular AF patients. Study design: Four thousand one hundred consecutive adult patients from 42 centers with at least one AF attack identified on electrocardiography will be included in the study. Patients with rheumatic mitral valve stenosis and prosthetic valve disease will be excluded from the study. At the end of one year, the patients will be evaluated in terms of major cardiac end points (death, transient ischemic attack, stroke, systemic thromboembolism, major bleeding and hospitalization). Results: First results are expected in June 2015. Data about major cardiovascular end-points will be available in January 2016. Conclusion: The rates and kind of oral anticoagulant use, TTR in vitamin K antagonist users and main management modality applied in non-valvular AF patients will be determined by AFTER-2 study. In addition, the rate of major adverse events (MACEs) and the independent predictors of these MACEs will be detected (AFTER-2 Study ClinicalTrials. gov number, NCT02354456.).en_US
dc.identifier.doi10.5543/tkda.2015.35984en_US
dc.identifier.endpage177en_US
dc.identifier.issn1016-5169en_US
dc.identifier.issue2en_US
dc.identifier.pmid25782122en_US
dc.identifier.scopusqualityQ4en_US
dc.identifier.startpage169en_US
dc.identifier.urihttps://dx.doi.org/10.5543/tkda.2015.35984
dc.identifier.urihttps://hdl.handle.net/20.500.12395/31828
dc.identifier.volume43en_US
dc.identifier.wosWOS:000421963600007en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakTR-Dizinen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherTURKISH SOC CARDIOLOGYen_US
dc.relation.ispartofTURK KARDIYOLOJI DERNEGI ARSIVI-ARCHIVES OF THE TURKISH SOCIETY OF CARDIOLOGYen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.selcuk20240510_oaigen_US
dc.subjectAnticoagulant agenten_US
dc.subjectatrial fibrillation/epidemiologyen_US
dc.subjectdrug utilizationen_US
dc.subjectelectrocardiographyen_US
dc.subjectinternational normalized ratioen_US
dc.subjectwarfarinen_US
dc.titleAn epidemiological study to evaluate the use of vitamin K antagonists and new oral anticoagulants among non-valvular atrial fibrillation patients in Turkey- AFTER-2 study designen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu